These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25488854)

  • 41. Cardiovascular complications in patients with diabetic nephropathy receiving pharmacological versus renal replacement therapy.
    Głowińska I; Grochowski J; Małyszko J
    Pol Arch Med Wewn; 2008; 118(7-8):404-12. PubMed ID: 18714735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies.
    Reichetzeder C; Tsuprykov O; Hocher B
    Life Sci; 2014 Nov; 118(2):141-8. PubMed ID: 24607774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Novel biomarkers for diabetic nephropathy].
    Araki S
    Rinsho Byori; 2014 Feb; 62(2):171-9. PubMed ID: 24800493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Microalbuminuria. From diabetes to cardiovascular risk].
    Monhart V
    Vnitr Lek; 2011 Mar; 57(3):293-8. PubMed ID: 21495411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy.
    Sarafidis PA; Lasaridis AN
    Nat Rev Nephrol; 2010 Aug; 6(8):447-9. PubMed ID: 20664627
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
    Lo MK; Lee KF; Chan NN; Leung WY; Ko GT; Chan WB; So WY; Ng MC; Ho CS; Tam JS; Lam CW; Tong PC; Chan JC
    Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy].
    Martínez-Castelao A; Ramos R; González MT; Castiñeiras MJ
    Nefrologia; 2002; 22 Suppl 1():51-8. PubMed ID: 11987671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors.
    Tarnow L
    Dan Med Bull; 2002 Feb; 49(1):19-42. PubMed ID: 11894722
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Albuminuria and diabetic nephropathy.
    Chang SS
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():974-9. PubMed ID: 18806713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
    McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
    Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diabetic nephropathy and cardiovascular risk].
    Rossi L; Gesualdo L
    G Ital Nefrol; 2017 Mar; 34(Suppl 69):104-118. PubMed ID: 28682032
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current concepts in the management of diabetic nephropathy.
    Waanders F; Visser FW; Gans RO
    Neth J Med; 2013 Nov; 71(9):448-58. PubMed ID: 24218418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glycosaminoglycan therapy for long-term diabetic complications?
    Gambaro G; Skrha J; Ceriello A
    Diabetologia; 1998 Aug; 41(8):975-9. PubMed ID: 9726602
    [No Abstract]   [Full Text] [Related]  

  • 57. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria.
    De Cosmo S; Bacci S; Piras GP; Cignarelli M; Placentino G; Margaglione M; Colaizzo D; Di Minno G; Giorgino R; Liuzzi A; Viberti GC
    Diabetologia; 1997 Oct; 40(10):1191-6. PubMed ID: 9349601
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The trend of new drug development for the treatment of diabetes mellitus].
    Kaku K
    Nihon Rinsho; 2015 Dec; 73(12):2108-14. PubMed ID: 26666161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diabetic nephropathy: Atrasentan stabilizes the endothelial glycocalyx.
    Allison SJ
    Nat Rev Nephrol; 2016 Jun; 12(6):315. PubMed ID: 27067526
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.